Resveratrol Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Patients With Type 2 Diabetes Mellitus

Abstract

SummaryResveratrol has been reported to have potent anti-atherosclerotic effects in animal studies. However, there are few interventional studies in human patients with atherosclerogenic diseases. The cardio-ankle vascular index (CAVI) reflects arterial stiffness and is a clinical surrogate marker of atherosclerosis. The aim of the present study was to investigate the effect of resveratrol on arterial stiffness assessed by CAVI in patients with type 2 diabetes mellitus (T2DM).In this double-blind, randomized, placebo-controlled study, 50 patients with T2DM received supplement of a 100-mg resveratrol tablet (total resveratrol: oligo-stilbene 27.97 mg/100 mg/day) or placebo daily for 12 weeks. CAVI was assessed at baseline and the end of study. Body weight (BW), blood pressure (BP), glucose and lipid metabolic parameters, and diacron-reactive oxygen metabolites (d-ROMs; an oxidative stress marker) were also measured.Resveratrol supplementation decreased systolic BP (-5.5 ± 13.0 mmHg), d-ROMs (-25.6 ± 41.8 U.CARR), and CAVI (-0.4 ± 0.7) significantly (P < 0.05) and decreased BW (-0.8 ± 2.1 kg, P = 0.083) and body mass index (-0.5 ± 0.8 kg/m 2 , P = 0.092) slightly compared to baseline, while there were no significant changes in the placebo group. Decreases in CAVI and d-ROMs were significantly greater in the resveratrol group than in the placebo group. Multivariate logistic regression analysis identified resveratrol supplementation as an independent predictor for a CAVI decrease of more than 0.5.In conclusion, 12-week resveratrol supplementation may improve arterial stiffness and reduce oxidative stress in patients with T2DM. Resveratrol may be beneficial in preventing the development of atherosclerosis induced by diabetes. However, a large-scale cohort study is required to validate the present findings. (Int Heart J 2017; 58: 577-583)

The Effect of Resveratrol Supplementation on Cardio‐Metabolic Risk Factors in Patients with Type 2 Diabetes: A Randomized, Double‐Blind Controlled Trial

“…Several trials have aimed to investigate the antiobesity effects of resveratrol in human. Contrary to our findings, some trials revealed significant effects of resveratrol supplementation on anthropometric measures in patients with T2DM (Imamura et al, 2017;Kumar & Joghee, 2013;Seyyedebrahimi, Khodabandehloo, Esfahani, & Meshkani, 2018). However, one study reached null results (Bo et al, 2016).…”

“…In addition, studies reported that resveratrol contributes to preventing the conversion of LDL-C to oxidized LDL (Liu, Chen, & Li, 2017). However, some human studies failed to show a beneficial effect of resveratrol supplementation (Bashmakov et al, 2014;Imamura et al, 2017). In a study conducted by Crandall et al, no significant change in lipid profile was observed following resveratrol supplementation in older adults (Crandall et al, 2012).…”

Association of Circulating Neuregulin-4 with Presence and Severity of Coronary Artery Disease

“…15) Inducing brown-like adipocyte formation in white adipose tissue (WAT) may be valuable to ameliorate arterial stiffness. 16) Nrg4 was recently identified as a brown-fat-enriched endocrine factor. It could be a key factor for the development of BAT and acquisition of BAT features of WAT depots by promoting the growth of neurites and thus enhancing innervation of the tissues needed to activate the thermogenic functions.…”

Resveratrol and the Interaction between Gut Microbiota and Arterial Remodelling

“…Surprisingly, resveratrol limits the increase in compliance of spontaneously hypertensive rat (SHR) by its inhibitory effect on arterial remodelling and ERK signalling rather than the effect on blood pressure or arterial wall stiffening [82]. In a recent double blind, randomized, placebo-controlled study, resveratrol supplementation has been shown to reduce arterial stiffness (measured by Cardio Ankle Vascular Index) in patients with type 2 diabetes [47].…”